Cancer Immunotherapy in Urology, An Issue of Urologic Clinics
- 1st Edition, Volume 47-4 - October 12, 2020
- Editors: Sujit S Nair, Ashutosh Tewari
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 7 5 4 9 8 - 9
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 7 5 4 9 9 - 6
The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Urologic Clinics of North America
- Preface
- William B. Coley: His Hypothesis, His Toxin, and the Birth of Immunotherapy
- Key points
- Introduction
- Early immunotherapy
- William B. Coley: “The most opportune time in a thousand years”
- Bacilli Calmette-Guérin: Urology’s immunotherapy success story
- The landmarks of immunologic discovery that provided the foundation for immunotherapy
- Checkpoint inhibitors
- Kidney Cancer: An Overview of Current Therapeutic Approaches
- Key points
- Introduction
- First-line combination therapies for metastatic renal cell carcinoma
- Second-line treatment strategies for metastatic renal cell carcinoma
- Adjuvant treatment in renal cell carcinoma
- Neoadjuvant therapy in renal cell carcinoma
- Future directions
- Summary
- Harnessing Natural Killer Cell Function for Genitourinary Cancers
- Key points
- Background
- Natural killer cells in bladder cancer
- Natural killer cells in kidney cancer
- Natural killer cells in prostate cancer
- Summary
- Clinical care points
- Immunotherapy for Localized Prostate Cancer: The Next Frontier?
- Key points
- Introduction
- Overview of the immune response and cancer
- Strategies for cancer immunotherapy
- Immunotherapy considerations for prostate cancer
- ProstVac-VF
- Sipuleucel-T
- Checkpoint inhibitor immunotherapy
- Future directions
- funding
- Summary
- The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer
- Key points
- Introduction
- Patient selection and timing of therapy
- The role of immunotherapy in prostate cancer
- Rationale for immunotherapy in biochemically recurrent prostate cancer
- Selected studies of immunotherapy in biochemically recurrent prostate cancer
- Immunotherapy for Prostate Cancer: Treatments for the “Lethal” Phenotype
- Key points
- Introduction
- Targeting the tumor microenvironment: a challenge?
- Lethal prostate cancer: does it exist and can we treat it?
- Treating the “lethal” phenotype based on genomics
- Immunotherapy in prime time: the role of biomarkers
- Discussion
- Application of Single-Cell Sequencing to Immunotherapy
- Key points
- Introduction
- Heterogeneity in urologic cancers
- Overview of single-cell sequencing approaches
- Technical considerations in single-cell sequencing
- Emerging technologies
- Summary
- Clinical comments
- Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options
- Key points
- Progression
- Immunotherapy in cancer
- Immunotherapy in genitourinary cancers
- Immunotherapy in bladder cancer
- Immunotherapy for metastatic prostate cancer
- Preclinical models for immunotherapy research for metastatic prostate cancer
- Future directions: combination therapy of vaccines and checkpoint inhibitors, with molecularly driven approaches
- Biotech and Breakthroughs in Immuno-Oncology
- Key points
- Special Article
- Personalized Medicine for the Infertile Male
- Key points
- Introduction
- Standard male infertility workup: what is the standard male infertility workup
- Spermatogenesis failure: the future for spermatogonia stem cell transplantation and genomic editing
- Seminal plasma (proteomics)
- Epigenetics (epigenomics)
- Susceptibility genes to environmental factors in male infertility
- Summary
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 47-4
- Published: October 12, 2020
- Imprint: Elsevier
- Hardback ISBN: 9780323754989
- eBook ISBN: 9780323754996